PCN Insights, News, Videos, and More
News
10/03/2024
High-dose psilocybin demonstrated an effect similar to escitalopram for the treatment of depressive symptoms in a recent systematic review and meta-analysis published in The BMJ.
High-dose psilocybin demonstrated an effect similar to escitalopram for the treatment of depressive symptoms in a recent systematic review and meta-analysis published in The BMJ.
High-dose psilocybin...
10/03/2024
Psych Congress Network
Videos
09/30/2024
Desiree Matthews, PMHNP-BC, CEO, Different MHP, highlights how providers can integrate medication management into their virtual practices—especially for patients needing long-acting injectable (LAI) antipsychotics.
Desiree Matthews, PMHNP-BC, CEO, Different MHP, highlights how providers can integrate medication management into their virtual practices—especially for patients needing long-acting injectable (LAI) antipsychotics.
Desiree Matthews, PMHNP-BC, CEO,...
09/30/2024
Psych Congress Network
News
09/27/2024
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug...
09/27/2024
Psych Congress Network
News
09/26/2024
A once-daily, 20 mg dose of an investigational oral muscarinic M4 selective agonist in development for adults with schizophrenia achieved its primary endpoint in a phase 2 trial, maker Neurocrine Biosciences announced.
A once-daily, 20 mg dose of an investigational oral muscarinic M4 selective agonist in development for adults with schizophrenia achieved its primary endpoint in a phase 2 trial, maker Neurocrine Biosciences announced.
A once-daily, 20 mg dose of an...
09/26/2024
Psych Congress Network
News
09/23/2024
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths...
09/23/2024
Psych Congress Network
Videos
09/18/2024
Timothy Wilens, MD, provides practical clinical guidance for supporting patients with ADHD through life transitions.
Timothy Wilens, MD, provides practical clinical guidance for supporting patients with ADHD through life transitions.
Timothy Wilens, MD, provides...
09/18/2024
Psych Congress Network
News
09/13/2024
The United States Food and Drug Administration (FDA) has granted clearance for DaylightRx, a prescription digital therapeutic designed to treat generalized anxiety disorder (GAD).
The United States Food and Drug Administration (FDA) has granted clearance for DaylightRx, a prescription digital therapeutic designed to treat generalized anxiety disorder (GAD).
The United States Food and Drug...
09/13/2024
Psych Congress Network
Q&As
09/09/2024
Join Craig Chepke, MD, DFAPA, medical director of Excel Psychiatric Associates, as he demystifies the complexities of lithium formulations.
Join Craig Chepke, MD, DFAPA, medical director of Excel Psychiatric Associates, as he demystifies the complexities of lithium formulations.
Join Craig Chepke, MD, DFAPA,...
09/09/2024
Psych Congress Network
News
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
Q&As
09/08/2024
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key...
09/08/2024
Psychiatry & Behavioral Health
